Compare GAM & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAM | TSHA |
|---|---|---|
| Founded | 1927 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | GAM | TSHA |
|---|---|---|
| Price | $63.98 | $6.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.63 |
| AVG Volume (30 Days) | 21.8K | ★ 2.6M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ 11.67 | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,152.42 |
| P/E Ratio | $5.54 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $52.69 | $2.25 |
| 52 Week High | $66.18 | $7.30 |
| Indicator | GAM | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 65.99 |
| Support Level | $62.61 | $4.39 |
| Resistance Level | $64.28 | N/A |
| Average True Range (ATR) | 1.20 | 0.41 |
| MACD | -0.19 | -0.02 |
| Stochastic Oscillator | 23.88 | 59.24 |
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations. The company invests principally in common stocks believed by management to have growth potential.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.